Boehringer Ingelheim recently announced European Union (EU) approval of nintedanib (brand name OFEV®) for idiopathic pulmonary fibrosis (IPF) treatment. The committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion, which means that the treatment can now be marketed, sold, and used…
Nintedanib Idiopathic Pulmonary Fibrosis Drug Receives Positive Opinion from CHMP in EU
Special cells may dump fat into the lungs of people with pulmonary fibrosis, filling airspaces. Scientists at Thomas Jefferson University in Philadelphia found that decreasing the accumulation of lung fat could help reduce problems associated with this disease. Pulmonary fibrosis is characterized by scarred, thick tissue within the lungs.
The Pulmonary Fibrosis Foundation has just published November’s schedule of ongoing fundraising events. With 10 different programs for getting involved to choose from this month, it should be easy to find something right up your alley, and help support research and development efforts for pulmonary fibrosis, as…
As the drug development community continues to invest into pulmonary fibrosis research, new insights are improving both diagnostic and prognostic tools for improving treatment of the disease. Recently, Pacific Therapeutics Ltd. scientists reported in a study entitled “Familial and sporadic idiopathic pulmonary fibrosis:making the diagnosis from peripheral blood”…
Pattern of alveolar oxygen exchange units on the surface of a mouse lung. Credit: Dr. Shou Ping Guan A recent study led by Professors Frank McKeon, Ph.D., and Wa Xian, Ph.D. from The Jackson Laboratory focused on a novel lung regeneration concept and how certain lung stem…
A new study on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) entitled “Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis” was published in Respiratory Research by Keishi Oda, part of Dr. Hiroshi Mukae’s group from the Department of Respiratory Medicine at University of Occupational and…
New stem cell research is offering insights into how scientists may someday be able to mitigate lung injury caused by diseases such as IPF. A recent study entitled “The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor” and published…
The Scleroderma Research Foundation will host a free, live webinar on the relationship between pulmonary fibrosis (PF) and scleroderma on Thursday, November 13, at 10:00 a.m. PST. The Director of Biological Research for the Interstitial Lung Disease Program at University of California San Francisco (UCSF), Paul Wolters, will be the main lecturer…
The chief executive officer and president of Pacific Therapeutics, a clinical stage specialty pharmaceutical company dedicated to the development of treatments for fibrosis and erectile dysfunction, commented on the recent interest of big pharmaceutical companies in acquiring therapies for the treatment of fibrosis. Doug Unwin said that…
The National Institutes of Health (NIH) recently granted a $15.6 million award to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD), to support five years of research on mucolytic agents. The agents were discovered by the developmental stage biopharmaceutical company Parion Sciences,…
